摘要
目的：应用翻译引进的改良疾病累计评分表（MCIRS）研究肺癌患者合并症分布情况及其对化疗安全性的影响。方法：采用MCIRS评估合并症。根据MCIRS评分、年龄及KPS分层研究化疗毒副反应发生率。结果：110例肺癌患者分成55～64岁、65—74岁、≥75岁3组，其中99例有合并症，每组平均MCIRS评分、合并症侵犯的系统数目和受4～5级合并症侵犯的系统数目均随着年龄的增大而增加（P〈0．05）。92例化疗的患者，随着MCIRS评分升高，恶心呕吐（P=0．035）、白细胞减少（P=0．042）、血红蛋白减少（P=0．022）、发热感染（P=0．039）和疲劳（P=0．038）的发生率显著增加。根据年龄、KPS分层未发现毒副反应发生率的变化。结论：影响肺癌患者化疗安全性的重要因素是合并症，而不是年龄。根据MCIRS评分预测毒副反应比KPS更敏感，MCIRS评分高的患者化疗需加强监护。
Objective：Use the modified cumulative illness rating scale brought in Chinese version to investigate the prevalence of comorbidity in patients with lung cacner, and its impact on chemotherapy safety. Methods： Comorbidity was assessed with the MCIRS. Stratified according to the score of MCIRS, age and karnofsky performance score（KPS） to study the incidence of chemotherapy toxicity. Results：One hundred and ten patients with lung cancer were divided into three groups by age ：55～64,65 ～ 74, ≥ 75. Nintynine cases had comorbidity. The average score of MCIRS,average number of affected organ systems,average number of affected organ system with severe disease （ levels 4-5 ） all increased with age（ P 〈 0. 05 ）. With the score of MCIRS rising, the occurrence rate of nausea and vomite （ P = 0. 035 ） , leukopenia （ P = 0. 042 ） , aglobulia （ P = 0. 022 ） , fever and infection （ P = 0. 039 ） , fatigue （ P = 0. 038 ） all significantly increased in 92 cases who accepted chemotherapy. There were no change in the incidence of toxicity when stratified by age or KPS. Conclusion：Comorbidity is the important factor affected chemotherapy safety of lung cancer,not age. According the score of MCIRS to predict chemotherapy toxicity is more sensitive than KPS. Stronger monitor is needed when patients with high sores of MCIRS accepted chemotherapy.
出处
《临床肿瘤学杂志》
CAS
2008年第1期55-58,共4页
Chinese Clinical Oncology
基金
安徽省民政厅资助项目(18-2-20)
